Science

Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers

November 18, 2021By

This examination of a large international sample of adults highlights the prominence of therapeutic and wellness motivations for microdosing psychedelic drugs and identified lower levels of anxiety and depression among microdosers relative to controls.  Comparisons of psilocybin to LSD microdosers indicated no differences on measures of Depression, Anxiety and Stress from the DASS-21 (all values for F (1, 827) < 1.0, p > 0.50). The inclusion of…

READ MORE
Biography/Memoir

Patents for psychedelics…

November 1, 2021By

…nearly every day, another psychedelics company announces its work in securing patents for the intellectual property represented by the product they developed… a quick search of the USPTO site shows that there are currently hundreds of patents related to LSD and Psilocybin products and formulations. Psilocybin (U.S. Patent No. 3,183,172, “Obtaining Psilocybin and Psilocin from…

READ MORE
Psychology

LSD vs. psilocybin microdosing for mental health and workplace productivity

October 28, 2021By

[Case reports]: LSD… was better for more puzzle-like creativity – for solo pondering over a question or engaging in a writing task…. …[psilocybin] reminded me of what psychologists call the fundamental attribution error, or the tendency to attribute someone else’s poor performance to inherent defects in their personality but blame our own slip-ups on someone else.…

READ MORE
Biography/Memoir

What [happened on]… 550 doses of LSD?

October 27, 2021By

The story of CB, a 49-year-old woman, and her roommate, who witnessed the event. CB had contracted Lyme disease in her early 20s, and by the LSD event, she experienced significant pain in her feet and ankles, routinely taking morphine for a decade… CB snorted… pure LSD – 550 times the normal recreational dosage of…

READ MORE
Science

Shrooms and lsd linked to lower heart disease and diabetes risk

October 13, 2021By

“The findings suggest that lifetime classic psychedelic use is associated with lower odds of having had heart disease or diabetes in the past year,” lead study author and Oxford sociologist Otto Simonsson, [said]. A team of scientists identified the unexpected trend after poring over ten years’ worth of data from the National Survey on Drug…

READ MORE
Science

…psychedelics boost brain growth factor levels?

May 15, 2021By

Brain-derived neurotrophic factor (BDNF) regulates neuronal development and survival and triggers adaptive neuroplasticity… animal studies have reported that acute and chronic administration of various psychedelic compounds, including LSD, psilocybin, DMT, and other ayahuasca-derived alkaloids, can increase BDNF production and neurogenesis (the formation of new neurons). Importantly, threats to our well-being such as stress, ageing and…

READ MORE
Science

The psychedelic research hiatus and its relevance today

May 4, 2020By

[In the 1950’s and 60’s] psychedelics were of little interest to pharmaceutical companies as the intervention seemed to treat illness, rather than alleviate symptoms. Consequently, the financial imperatives were lacking; fully recovered patients would not require continued medication… Sandoz was reluctant to share such proprietary and patented data (Bonson, 2018). When required by the FDA, the company…

READ MORE
Biography/Memoir

NYC pharma startup wants to turn LSD into…

April 16, 2020By

“…I want nothing to do with those kinds of folks who want to decriminalize psychedelics,” he says [a 32-year-old former Uber employee and co-founder]. …[he is part of] one of many companies trying to repurpose hallucinogenic molecules as the next blockbuster drug… has acquired the exclusive rights to eight clinical trials that are exploring the…

READ MORE